{"id":1361,"date":"2026-04-15T15:00:00","date_gmt":"2026-04-15T15:00:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1361"},"modified":"2026-03-19T19:57:59","modified_gmt":"2026-03-19T19:57:59","slug":"thymosin-alpha-1-immune-peptide-research-guide","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/","title":{"rendered":"Thymosin Alpha-1: Immune Peptide Research, Mechanisms &#038; Preclinical Findings"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Thymosin_Alpha-1_Immune_Peptide_Research_Mechanisms_Preclinical_Findings\" >Thymosin Alpha-1: Immune Peptide Research, Mechanisms &#038; Preclinical Findings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Chemical_Identity\" >Chemical Identity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Discovery_Story\" >Discovery Story<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Mechanism_of_Action\" >Mechanism of Action<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Cytokine_Profile\" >Cytokine Profile<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Zadaxin_The_Regulatory_Story\" >Zadaxin: The Regulatory Story<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Preclinical_Data\" >Preclinical Data<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Not_TB-500_Dont_Confuse_Them\" >Not TB-500. Don&#8217;t Confuse Them.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Safety_Profile\" >Safety Profile<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Where_It_Stands_Legally\" >Where It Stands Legally<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Research_Availability\" >Research Availability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#Conclusion\" >Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/lotilabs.com\/resources\/thymosin-alpha-1-immune-peptide-research-guide\/#References\" >References<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Thymosin_Alpha-1_Immune_Peptide_Research_Mechanisms_Preclinical_Findings\"><\/span>Thymosin Alpha-1: Immune Peptide Research, Mechanisms &#038; Preclinical Findings<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n\n<p>35+ countries have approved it. The FDA gave it orphan drug status for four separate indications. It&#8217;s been studied continuously since 1977. And most Western researchers couldn&#8217;t pick it out of a lineup.<\/p>\n\n<p><a href=\"https:\/\/lotilabs.com\/product\/thymosin-alpha-1-10mg\/\">Thymosin Alpha-1<\/a> \u2014 T\u03b11. 28 amino acids from the thymus gland. It fires up TLR2 and TLR9 simultaneously, matures dendritic cells, pushes T-cell differentiation, and supercharges NK cell killing. The synthetic version goes by thymalfasin (brand name Zadaxin), and it&#8217;s been deployed against hepatitis B and C across Asia for years. In America? Investigational. Go figure.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Chemical_Identity\"><\/span>Chemical Identity<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Twenty-eight residues. Acetylated serine at the N-terminus. Derived from prothymosin alpha \u2014 a larger 109-amino acid precursor that thymic epithelial cells chop up and release into circulation.<\/p>\n\n<ul>\n<li><strong>Sequence:<\/strong> Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN<\/li>\n<li><strong>Molecular Formula:<\/strong> C\u2081\u2082\u2089H\u2082\u2081\u2085N\u2083\u2083O\u2085\u2085<\/li>\n<li><strong>Molecular Weight:<\/strong> 3,108.3 g\/mol<\/li>\n<li><strong>CAS:<\/strong> 62304-98-7<\/li>\n<\/ul>\n\n<p>Heavily acidic \u2014 loaded with aspartate and glutamate residues. Net negative charge at physiological pH. That charge profile shapes how it binds receptors and separates it structurally from the other famous thymosin: <a href=\"https:\/\/lotilabs.com\/resources\/thymosin-beta-4-tissue-regeneration\/\">thymosin beta-4 (TB-500)<\/a>, which weighs in at 4,921 g\/mol and does tissue repair instead of immune modulation. Same family name. Entirely different biology.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Discovery_Story\"><\/span>Discovery Story<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>1960s. Allan Goldstein and Abraham White at Albert Einstein College of Medicine. They&#8217;re studying why the thymus gland matters for immune development. From calf thymus tissue they isolate &#8220;thymosin fraction 5&#8221; \u2014 a crude peptide soup that enhances immune function in animal models (Goldstein, 2007; Ann N Y Acad Sci 1112:1-13).<\/p>\n\n<p>Ten years of purification work later, 1977: they pull out one specific 28-amino acid peptide from that fraction. Thymosin alpha-1. First individual peptide isolated from the thymic mixture that kept its immunological punch. The sequence got mapped. Production in rat thymus was confirmed (Hannappel &#038; Huff, 1984; Proc Natl Acad Sci USA 81:1008-1011).<\/p>\n\n<p>SciClone Pharmaceuticals later synthesized it as thymalfasin (Zadaxin) \u2014 identical amino acid sequence to the natural peptide. That synthetic version became the basis for regulatory filings across 35+ countries. From crude thymic extract to a defined, synthesized compound with international approvals. Took about three decades.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Mechanism_of_Action\"><\/span>Mechanism of Action<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Not a one-trick peptide. T\u03b11 orchestrates immune responses across innate and adaptive systems at the same time. Multiple receptor targets. Multiple cell types.<\/p>\n\n<h3>TLR2 + TLR9: Both At Once<\/h3>\n\n<p>Most immune compounds hit one receptor. T\u03b11 hits two Toll-like receptors on myeloid and dendritic cells.<\/p>\n\n<p>Through TLR9: MyD88 cascade fires. IRF-7 gets activated. Cells pump out IFN-\u03b1 \u2014 type I interferon. First-line antiviral defense. Through TLR2: NF-\u03baB translocates to the nucleus. Now you&#8217;re getting IL-12, TNF-\u03b1, IL-6. Phagocytes wake up. Microbial recognition gets cranked.<\/p>\n\n<p>The two arms amplify each other. TLR9&#8217;s IFN-\u03b1 boosts the scale of TLR2-driven responses. Coordinated, not additive (Romani et al., 2006; Blood 108(7):2265-2274).<\/p>\n\n<h3>Dendritic Cells: From Immature to Armed<\/h3>\n\n<p>T\u03b11 matures dendritic cells. MHC class I and II go up. Co-stimulatory molecules (CD80\/CD86) come online. Antigen processing capacity ramps.<\/p>\n\n<p>But it&#8217;s not just activation. T\u03b11 also flips on IDO \u2014 indoleamine 2,3-dioxygenase \u2014 in DCs. That&#8217;s tryptophan catabolism. Creates a regulatory environment. Inflammation gets balanced against tolerance (Romani et al., 2006). Gas pedal and brake at the same time.<\/p>\n\n<h3>T Cells: The Core Function<\/h3>\n\n<p>Classic T\u03b11 territory. Thymic progenitors \u2192 functional CD4+ helpers and CD8+ killers. The two pillars of cellular immunity. But there&#8217;s more:<\/p>\n\n<ul>\n<li>Tilts Th1\/Th2 toward Th1 \u2014 cell-mediated over antibody-driven. Th17 and Treg populations also shift<\/li>\n<li>Immunocompromised animals: T-cell counts partially restored. Function recovers. Rosette percentages climb<\/li>\n<li>Boosts T-cell-dependent antibody production \u2014 hence the vaccine adjuvant research<\/li>\n<\/ul>\n\n<h3>NK Cells<\/h3>\n\n<p>Innate immune system&#8217;s hit squad. T\u03b11 activates their killing capacity directly \u2014 activating receptors get upregulated, IFN-\u03b3 production spikes, and there&#8217;s synergy with IL-2 for proliferation.<\/p>\n\n<p>Different immunomodulatory angle: <a href=\"https:\/\/lotilabs.com\/resources\/kpv-peptide-top-benefits-and-uses-for-gut-health-and-inflammation\/\">KPV peptide<\/a> works through alpha-MSH receptors instead.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Cytokine_Profile\"><\/span>Cytokine Profile<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>T\u03b11&#8217;s signature: it boosts protective immune cytokines while damping inflammatory damage. That dual action is what makes it an immunomodulator rather than just an immune stimulant.<\/p>\n\n<table>\n<thead>\n<tr><th>Cytokine<\/th><th>Direction<\/th><th>How<\/th><th>What It Means<\/th><\/tr>\n<\/thead>\n<tbody>\n<tr><td>IFN-\u03b1<\/td><td>\u2191<\/td><td>TLR9 \u2192 IRF-7<\/td><td>Antiviral innate response<\/td><\/tr>\n<tr><td>IFN-\u03b3<\/td><td>\u2191<\/td><td>NK and T-cell activation<\/td><td>Cellular immunity, macrophage priming<\/td><\/tr>\n<tr><td>IL-2<\/td><td>\u2191<\/td><td>T-cell cascade<\/td><td>T-cell proliferation<\/td><\/tr>\n<tr><td>IL-10<\/td><td>\u2191<\/td><td>Treg and DC modulation<\/td><td>Anti-inflammatory balance<\/td><\/tr>\n<tr><td>IL-12<\/td><td>\u2191<\/td><td>TLR2 \u2192 NF-\u03baB<\/td><td>Th1 polarization, NK boost<\/td><\/tr>\n<tr><td>IL-1\u03b2<\/td><td>\u2193<\/td><td>Inflammasome regulation<\/td><td>Less inflammatory tissue damage<\/td><\/tr>\n<tr><td>TNF-\u03b1<\/td><td>\u2193<\/td><td>Anti-inflammatory modulation<\/td><td>Controlled immune response<\/td><\/tr>\n<\/tbody>\n<\/table>\n\n<p>Protective cytokines go up. Damage cytokines come down. IL-10 \u2014 tolerance \u2014 also rises. It&#8217;s an unusually balanced profile. Most immune compounds tilt one direction. T\u03b11 manages to push immunity harder while simultaneously putting a leash on inflammatory damage. That&#8217;s rare.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Zadaxin_The_Regulatory_Story\"><\/span>Zadaxin: The Regulatory Story<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>SciClone Pharmaceuticals turned T\u03b11 into thymalfasin, sold as Zadaxin \u2014 a 1.6 mg subcutaneous injection. Here&#8217;s where it stands:<\/p>\n\n<ul>\n<li>Approved in 35+ countries for hepatitis B\/C research and immune enhancement<\/li>\n<li>FDA orphan drug designation for: malignant melanoma, chronic active hepatitis B, DiGeorge anomaly with immune defects, and hepatocellular carcinoma<\/li>\n<li>Phase II completed for hep B, Phase III for hep C in the US<\/li>\n<li>Not approved in the US (beyond orphan designation), Japan, or most of Europe. Italy is the notable exception<\/li>\n<\/ul>\n\n<p>Regulatory status varies enormously by country. In the US and EU, T\u03b11 remains investigational.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Preclinical_Data\"><\/span>Preclinical Data<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h3>Hepatitis B<\/h3>\n<p>Enhanced viral clearance markers. Improved T-cell responses to HBV antigens. Modulated hepatic inflammation. Multiple research groups have examined thymalfasin in HBV models \u2014 Chien et al. (1998), Mutchnick et al. (1999), Zavaglia et al. (2000) \u2014 with varying designs and endpoint measurements.<\/p>\n\n<h3>Fungal Infections<\/h3>\n<p>TLR2 is a primary receptor for fungal cell wall components. That makes T\u03b11&#8217;s TLR2 agonism directly relevant. In immunocompromised animal models: improved fungal clearance and survival.<\/p>\n\n<h3>Immunodeficiency Recovery<\/h3>\n<p>Chemotherapy tanks the immune system. T\u03b11 in these models: accelerated immune recovery, increased T-cell counts, improved functional markers. It&#8217;s been studied as an adjunctive agent during immunosuppressive treatment.<\/p>\n\n<h3>Oxidative Stress<\/h3>\n<p>Beyond immune effects: T\u03b11 protected against oxidative damage by boosting liver SOD and glutathione peroxidase activity (Armutcu et al.). Cytoprotection on top of immune modulation.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Not_TB-500_Dont_Confuse_Them\"><\/span>Not TB-500. Don&#8217;t Confuse Them.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>&#8220;Thymosin&#8221; is in both names. That&#8217;s where the overlap stops.<\/p>\n\n<p>T\u03b11: 28 amino acids, 3,108 g\/mol. Immune modulation \u2014 TLRs, dendritic cells, T cells, NK cells. Research focus: infection models, immune recovery.<\/p>\n\n<p>TB-500 (thymosin beta-4): 43 amino acids, 4,921 g\/mol. Tissue repair \u2014 actin dynamics, cell migration, angiogenesis. Research focus: wound healing, cardiac remodeling.<\/p>\n\n<p>Same family. Completely different biology. TB-500 deep dive: <a href=\"https:\/\/lotilabs.com\/resources\/thymosin-beta-4-tissue-regeneration\/\">thymosin beta-4 tissue regeneration guide<\/a>.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Safety_Profile\"><\/span>Safety Profile<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Favorable across preclinical studies. Key points:<\/p>\n\n<ul>\n<li>Minimal adverse findings at standard research concentrations in animal models<\/li>\n<li>Thymalfasin studied at 1.6 mg subcutaneous in investigational protocols<\/li>\n<li>Anti-apoptotic: T\u03b11 antagonizes dexamethasone-induced thymocyte death in a time- and dose-dependent manner (Baumann et al., 2000; Int J Immunopharmacol 22(12):1057-1066)<\/li>\n<li>Standard peptide storage requirements \u2014 temperature and handling matter for bioactivity<\/li>\n<\/ul>\n\n<h2><span class=\"ez-toc-section\" id=\"Where_It_Stands_Legally\"><\/span>Where It Stands Legally<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Approved in Asia and parts of Europe. FDA orphan designation but no US approval. Investigational in Japan and most Western countries except Italy. For research use \u2014 verify your jurisdiction&#8217;s rules.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Research_Availability\"><\/span>Research Availability<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>From Loti Labs:<\/p>\n\n<ul>\n<li><a href=\"https:\/\/lotilabs.com\/product\/thymosin-alpha-1-10mg\/\">Thymosin Alpha-1 10mg<\/a> \u2014 $79.99<\/li>\n<li><a href=\"https:\/\/lotilabs.com\/product\/ll-37-5mg\/\">LL-37 5mg<\/a> \u2014 $94.99 (cathelicidin antimicrobial peptide \u2014 innate immune defense, distinct mechanism)<\/li>\n<\/ul>\n\n<p>Also relevant: <a href=\"https:\/\/lotilabs.com\/resources\/kpv-peptide-top-benefits-and-uses-for-gut-health-and-inflammation\/\">KPV peptide<\/a> for alpha-MSH-mediated anti-inflammatory research.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Forty-plus years of data. Approvals on three continents. A mechanism that simultaneously strengthens protective immunity and controls inflammatory damage \u2014 TLR2 and TLR9 engagement, dendritic cell maturation, T-cell differentiation, NK activation, and a cytokine profile that goes up where it should and down where it should.<\/p>\n\n<p>The open research fronts: DC biology and immune tolerance characterization, synergy with other immunomodulators, and immune recovery in post-immunosuppressive settings. For a peptide that&#8217;s been studied since 1977 and is still generating new mechanistic insights, T\u03b11 has staying power that most research compounds don&#8217;t.<\/p>\n\n<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"References\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<ol>\n<li>Goldstein AL. History of the discovery of the thymosins. <em>Ann N Y Acad Sci.<\/em> 2007;1112:1-13. PMID: 17468229<\/li>\n<li>Romani L, et al. Thymosin alpha 1 activates dendritic cell tryptophan catabolism. <em>Blood.<\/em> 2006;108(7):2265-2274. PMID: 16740584<\/li>\n<li>Hannappel E, Huff T. Thymosins: prothymosin alpha, parathymosin, and beta-thymosins. <em>Vitam Horm.<\/em> 2003;66:257-296. PMID: 12852258<\/li>\n<li>Baumann CA, et al. T\u03b11 antagonizes dexamethasone-induced apoptosis of murine thymocytes. <em>Int J Immunopharmacol.<\/em> 2000;22(12):1057-1066. PMID: 11137614<\/li>\n<li>Garaci E, et al. Thymosin alpha 1 in oncology: preclinical and clinical experiences. <em>Expert Opin Biol Ther.<\/em> 2015;15(Suppl 1):S31-S39. PMID: 26096835<\/li>\n<li>Costantini C, et al. Reappraisal of thymosin alpha 1 in cancer research. <em>Front Oncol.<\/em> 2019;9:873. PMID: 31572680<\/li>\n<li>Billich A. Thymosin alpha 1 \u2014 SciClone Pharmaceuticals. <em>Curr Opin Investig Drugs.<\/em> 2002;3(5):698-707. PMID: 12090542<\/li>\n<li>Armutcu F, et al. T\u03b11 attenuates lipid peroxidation in fructose-induced steatohepatitis. <em>Clin Biochem.<\/em> 2005;38(6):540-547.<\/li>\n<li>Yang X, et al. Effect of T\u03b11 on Th1, Th2, Th17, and Treg subpopulations in vitro. <em>Braz J Med Biol Res.<\/em> 2012;45(1):25-32.<\/li>\n<li>Giuliani C, et al. T\u03b11 regulates MHC class I expression at transcriptional level. <em>Eur J Immunol.<\/em> 2000;30(3):778-786.<\/li>\n<li>FDA. Thymosin Alpha-1 Related Bulk Drug Substances. <em>Office of Pharmaceutical Quality Assessment II.<\/em> 2024.<\/li>\n<li>Chien RN, et al. Efficacy of thymosin alpha 1 in chronic hepatitis B. <em>Hepatology.<\/em> 1998;27(5):1383-1387. PMID: 9581696<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Research guide on Thymosin Alpha-1, approved in 35+ countries with FDA orphan drug status. Covers dendritic cell maturation, T-cell activation, TLR signaling, and immunomodulatory mechanisms.<\/p>\n","protected":false},"author":1,"featured_media":1388,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1361","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=1361"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1361\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/1388"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=1361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=1361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=1361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}